Publications

Replicative Instability Drives Cancer Progression. Morris BB, Smith JP, Zhang Q, et al.

Factors Predicting Participation in the Prospective Genomic Sequencing Study, Total Cancer Care (TCC), in Kentucky. Riggs MJ, Huang B, Chen Q, et al.

Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma. Coleman S, Xie M, Tarhini AA, et al.

Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. Peres LC, Colin-Leitzinger CM, Teng M, et al.

Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma. Hasipek M, Grabowski D, Guan Y, et al.

Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes. Hutchcraft ML, Lin N, Zhang S, et al.

MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung Adenocarcinoma. Morris Benjamin B., Wages Nolan A., Grant Patrick A., et al.

Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma. Koomen DC, Meads MB, Magaletti DM, et al.

Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy. Zaman S, Hajiran A, Coba GA, et al.

Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. Mostofa A, Distler A, Meads MB, et al.